These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 37919093)

  • 1. Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms.
    Morgan CJA
    Addiction; 2023 Dec; 118(12):2455-2456. PubMed ID: 37919093
    [No Abstract]   [Full Text] [Related]  

  • 2. The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada.
    Glynos NG; Kruger DJ; Kolbman N; Boehnke K; Lucas P
    J Psychoactive Drugs; 2023; 55(5):660-671. PubMed ID: 37516904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing.
    Qiu TT; Minda JP
    J Psychoactive Drugs; 2023; 55(2):123-133. PubMed ID: 35438609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts.
    Kratina S; Mayo LM
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):541-545. PubMed ID: 37734058
    [No Abstract]   [Full Text] [Related]  

  • 6. Psychologists' and psychotherapists' knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics.
    Kucsera A; Suppes T; Haug NA
    Clin Psychol Psychother; 2023; 30(6):1369-1379. PubMed ID: 37394242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.
    Johnson MW; Garcia-Romeu A; Johnson PS; Griffiths RR
    J Psychopharmacol; 2017 Jul; 31(7):841-850. PubMed ID: 28095732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belief changes associated with psychedelic use.
    Nayak SM; Singh M; Yaden DB; Griffiths RR
    J Psychopharmacol; 2023 Jan; 37(1):80-92. PubMed ID: 36317643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision.
    Hendricks PS; Clark CB; Johnson MW; Fontaine KR; Cropsey KL
    J Psychopharmacol; 2014 Jan; 28(1):62-6. PubMed ID: 24399338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships of classic psychedelic use with criminal behavior in the United States adult population.
    Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G
    J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy.
    Walsh Z; Thiessen MS
    Int Rev Psychiatry; 2018 Aug; 30(4):343-349. PubMed ID: 30251904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
    Holoyda B
    Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelia: The interplay of music and psychedelics.
    Jerotic K; Vuust P; Kringelbach ML
    Ann N Y Acad Sci; 2024 Jan; 1531(1):12-28. PubMed ID: 37983198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms.
    Tariq R
    Curr Rev Clin Exp Pharmacol; 2023; 18(2):94-109. PubMed ID: 35319407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
    Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J
    J Psychoactive Drugs; 2022; 54(4):309-318. PubMed ID: 34468293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.